Biomedical subjects

M I Garbuzov

Publications and source records attributed to M I Garbuzov.

At least 19 recordsLinked to original sources

PubMed2001

[Photodynamic therapy of recurrent and residual oropharyngeal and laryngeal tumors].

Photodynamic therapy (PDT) was given to 61 patients with recurrent cancer of the tongue, oral mucosa, lower lip, oro- and nasopharynx, larynx. Photosensitizers photogem and photosens of Russian produce were employed. The radiation was given twice with the interval 24 and 48 hours, the exposure to light 3 to 30 min. The impact was external, through the instrumental canal of the fibroscope, by intracavitary and interstitial techniques. The response was assessed within 4-6 weeks after the PDT course. The effect was observed in 95.1% patients. Its duration ranged from 4 months to 5 years. Complete resorption of the tumor was achieved in 57.4%. The treatment failed in 4.9% patients.

Aged↗

PubMed1995

[The radiation therapy of skin cancer (fractionation variants and methodology)].

Explore the source record for details and available documents.

Aged↗

PubMed1995

[The radiation therapy of skin cancer of the face].

Results of three-year radiotherapy are assessed in 586 patients with skin cancer, with tumors localized on the skin of the face in 484 of these. The results of treatment were found to depend on the histological structure of the tumor and disease stage: 100% cure was attained in patients with basal-cell carcinomas and T1 stage, whereas only 7% of patients with T4 stage were cured; in patients with squamous-cell carcinoma these figures were, respectively, 96.2 and 10%.

Adult↗

PubMed1990

[Radiotherapy of cancer of the lower lip].

The authors assessed the results of radiotherapy including tele- and brachytherapy (taking into account a cosmetic effect) of 261 patients with lower lip cancer (stage II in 160 patients and stage III in 101 patients). Teletherapy at a summary focal dose of (SFD) 20-24 Gy and a single focal dose (SFD) of 2 Gy was followed after 2-week interruption by brachytherapy, the SFD being 50-65 Gy mostly 50-55 Gy. An irradiation field size (0.5-1 sm from visible tumor limits) and SFD were determined by a stage of disease and infiltration depth. The cure rate during a 3-year follow-up in stage II was 91.2% in stage III--62%.

Aged↗

PubMed1990

[Radiotherapy with local SHF hyperthermia of the late stages of cancer of the mouth and oropharyngeal mucosa].

Thermoradiotherapy (local UHF-hyperthermia at 915 MHz and radiation therapy in the regimen of dynamic fractionation) of cancer of the oral and nasopharyngeal mucosa in patients with stages III-IV led to the 18-mos. survival of 32.5%, radiation therapy alone - to 18.3%. Hyperthermia enhanced radiation reactions of the normal mucosa.

Adult↗

PubMed1989

[A multi-fractionated course of gamma teletherapy in the late stages of cancer of the maxillofacial area and neck].

The results of gamma-beam therapy using a multifractional course in 373 patients with advanced stages of different parts of the maxillofacial area and neck were assessed. The 3-year survival rates among patients with stage IV (83.9%) were 18.8% for cancer of the organs of the oral cavity and 16.8% for cancer of the accessory nasal sinus and nose. Multifractional radiotherapy puts an end to painful symptoms in patients at advanced stages of cancer without causing any noticeable local reactions or deterioration in the patients' general status.

Adult↗

PubMed1989

[Thermoradiotherapy of the late stages of cancer of the oral mucosa and oropharynx].

Local UHF-hyperthermia (915 MHz) of cancer of the oral mucosa at advanced stages ensures higher immediate cure rates (48.9 +/- 7.5%) as compared to radiotherapy (26.8 +/- 6.9%). 30-min. hyperthermia before irradiation turned out more effective than 60-min. hyperthermia. Hyperthermia was attended by side-effects (fatigue and sweating, vertigo and pain in the zone of heating). Hyperthermia was not tolerated by 10.7% of patients. Fixed metal prostheses and crowns in the zone of planned hyperthermia should be removed.

Adult↗

PubMed1986

[Efficacy of radiotherapy of cancer of the mouth mucosa].

An analysis of 10-year experience of a radiological department (962 patients) indicated late admission of oral mucosa cancer patients for specialized treatment: 75-85% of the patients were admitted with Stage II-IV disease. The assessment of the efficacy of radiotherapy according to the 3 and 5-year survival rates showed that better results were obtained for buccal mucosa cancer and the worst for mouth fundus cancer. Three-year survival rates could be considered sufficient for the assessment of buccal cancer therapy whereas a 5-year period was necessary for the rest of the cancer sites. Therapeutic results and stage were well correlated; in all the sites the results were worse in patients with Stage III-IV disease. Regional metastases are a poor prognostic sign, particularly fixed metastases in patients with tongue and mouth fundus cancer. Combined therapy turned out to be the most effective in tongue cancer. In different variants of dose delivery in time the most favorable results were obtained with small fractionation (a conventional course). However it should be noted that a split course was usually applied to weak elderly patients with advanced stages of disease.

Carcinoma, Squamous Cell↗

PubMed1982